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Background: Cystic fibrosis (CF) patients are subjected to increased oxidative stress due to chronic pulmonary inflammation and recurrent
infections. Additionally, these patients have diminished skeletal muscle performance and exercise capacity. We hypothesize that a mixture of
multiple micronutrients could have beneficial effects on pulmonary function and muscle performance.
Methods: A double-blind, randomized, placebo controlled, cross-over trial with a mixture of multiple micronutrients (ML1) was performed
in 22 CF patients (12.9±2.5 yrs) with predominantly mild lung disease. Anthropometric measures, pulmonary function, exercise performance
by bicycle ergometry, muscular strength and vitamins A and E were determined.
Results: Analysis was performed using the paired Student t-test comparing the change in each parameter during ML1 and placebo. Plasma
vitamin E and A levels increased during ML1 when compared to placebo. However, no significant difference between the effect of the ML1
or placebo was observed neither for FEV1, FVC, anthropometry, nor for the parameters for muscle performance.
Conclusions: The micronutrient mixture was not superior to placebo with respect to changes in pulmonary function or muscle performance
in pediatric CF patients, despite a significant increase in plasma vitamin E concentrations.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Micronutrients; Children; Cystic fibrosis1. Introduction
Cystic fibrosis (CF) is an autosomal recessive inherited
disorder primarily characterized by chronic pulmonary
infection and inflammation [1,2]. During active infection
neutrophils and macrophages generate reactive oxygen⁎ Corresponding author. Tel.: +31 30 2504001; fax: +31 30 2505342.
E-mail address: pos.oudshoorn@planet.nl (J.H. Oudshoorn).
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doi:10.1016/j.jcf.2006.05.005species (ROS), which are necessary for bacterial killing,
but may be harmful when tissue antioxidant capacity is
exceeded [3]. Despite routine supplementation with fat
soluble vitamins, such as the antioxidants vitamin E and
carotenoids, biochemical markers for a disturbed oxidant–
antioxidant balance remain present in many CF patients [4–
7]. Therefore, several studies concerning micronutrient
supplements have been performed in CF patients, using
various amounts of α-tocopherol, retinol, ascorbic acid, and
carotenoids. These studies have shown beneficial effects oned by Elsevier B.V. All rights reserved.
Table 1
Composition of the micronutrient mixture ML1
100 ml 100 ml
Energy
value
kcal 80 Protein (casein:whey=1:1) g 6.0
En% 30
kJ 335 Carbohydrates (lactose,
saccharose, organic acids)
g 7.1
En% 35
Fat (linoleic acid 0.8) g 3.1
En% 35
Minerals: Vitamins:
Na mg 43 A μg REa 267
K mg 300 D μg 2.0
Cl mg 81 C (ascorbic acid) mg 100
Ca mg 126 E (α-tocopherol) mg 215
P mg 73 B1 (thiamine) mg 10
Mg mg 8 B2 (riboflavin) mg 1.2
B3 (pantothenate) mg 1.6
B5 (niacin) mg NEb 8.0
B6 (pyridoxine) mg 2.4
B11 (folic acid) μg 240
B12 (cobalamin) μg 1.2
Biotin (vit H) μg 40
Trace
elements:
Others:
Fe mg 0.4 Carnitine mg 1200
Zn mg 6.0 Choline mg 40
Cu mg 0.6 Creatine mg 1200
Mn mg 1.2 Taurine mg 1200
F mg 0.4 Coenzyme Q10 mg 60
Mo μg 20
Se μg 20
Cr μg 13
I μg 40
a Retinol equivalents.
b Niacine equivalents.
Table 2
Baseline clinical characteristics of the 22 remaining CF patients1,2
Subjects
(n=22)
Male : Female 10: 12
Age (years) 12.9±2.5
Height (m) 1.51±0.12
(in SDS) (−0.9±1.0)
Weight (kg) 42.2±12.6
(Weight-for-Height in SDS) (−0.01±1.0)
BMI (kg/m2) 18.0±3.1
(in SDS) (−0.3±1.2)
FFM (kg) 28.8±7.8
Skinfolds (sum of 4; in mm) 34.6±18.4
FEV1 (ml) 2130±584
FEV1 (% predicted) 87.2±17.0
FVC (ml) 2745±680
Isometric muscle force (sum of 6; in N) 1244±241
1Values given as mean±SD.
2BMI; body mass index, FFM; fat free mass calculated from four standard
skinfold measurements, FEV1; forced expiratory volume in one second,
FVC; forced vital capacity, isometric muscleforce; summed maximal force
in six muscle groups.
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has been reported for pulmonary function [8–12].
Physical exercise programs can improve exercise toler-
ance and pulmonary function in CF patients, mainly as a
result of increased muscle mass [13,14]. However, it turned
out to be extremely difficult for the participants in these
studies to maintain the increased exercise training, and just a
few still complied after one year. A nutritional supplement
might therefore be an important addition to exercise to
optimize muscle strength. As positive effects of creatine,
carnitine and taurine on muscle mass and/or performance in
athletes have been described [15–17] an increased intake of
these components might also be associated with an improved
exercise tolerance in CF patients.
Since CF is characterized by both oxidative stress and
poor exercise tolerance, we hypothesized that children with
CF might benefit from a mixture of micronutrients with
antioxidant and muscle fortifying action. It was anticipated
that initial effects of this mixture, such as improvement of
oxidant–antioxidant balance and muscle performance, could
be observed within the study period of three months
[11,15,16], while for other parameters, such as FEV1, a
favorable trend might become detectable within the same
timeframe.2. Methods
2.1. Subjects and study design
Thirteen boys and sixteen girls with CF aged 9.8–
18.9 years (mean 13.3 yrs) with predominantly mild
pulmonary disease were recruited from the CF centre of the
Wilhelmina Children's Hospital, University Medical Centre
Utrecht. Included were children aged 9 to 18 years with a
stable clinical condition (i.e., no need for oral or IVantibiotic
treatment other than chemoprophylaxis in the two months
prior to testing), absence of musculoskeletal disorders and an
FEV1 of ≥70% predicted. The study protocol was approved
by the UMCMedical Ethics Committee, and each participant
and/or the parents gave informed consent. In a cross-over
design each participant received once daily 100 ml of a liquid
micronutrient mixture (ML1) for three months, or 100 ml
placebo with a wash-out period of three months. The
composition of ML1 is described in Table 1.
The placebo tasted the same, contained identical amounts
of protein, carbohydrates and fats, but lacked the micro-
nutrients. Four female and two male participants (three on
placebo and three on ML1) dropped out of the study during
the first few weeks because of unpleasant taste of the
mixture. One boy did not complete the entire study due to the
emotional impact of a non-study CF related complication.
One participant could not perform the bicycle tests at the
measurements after both ML1 and placebo, first because of a
soccer injury and secondly because of a broken leg.
Because of small stature two participants performed a
standardized treadmill test (endurance) instead of the
bicycle tests [18]. Finally, 22 patients, with a mean age of
12.9±2.5 years, were available for analysis. The clinical
characteristics of these 22 subjects are described in Table 2.
Table 3
Baseline results for anaerobic and aerobic performance1,2
Subjects
(n=22)
Anaerobic performance
Ppeak (Watt) 538±236
Ppeak/FFM (Watt/kg LBM) 15.0±3.5
Pmean (Watt) 312±129
Pmean/FFM (Watt/kg LBM) 8.7±1.7
Aerobic performance
Wmax (Watt) 139±41
VO2max (ml/min) 1581±433
VO2max (ml/kg/min) 38±6
1Values given as mean±SD.
2Ppeak; peak power measured by WAnT, Pmean; mean power measured by
WAnT, LBM; lean body mass, Wmax; cycling maximal workload, VO2max;
maximal oxygen consumption during bicycle ergometry.
Table 4
Effect of micronutrient mixture (ML1) on clinical characteristics1,2
Changes
during ML1
Changes
during placebo
P value
BMI (kg/m2) 0.3±0.6 0.2±0.9 0.46
Sum of 4
skinfolds (mm)
1.6±4.6 2.8±9.8 0.65
FFM (kg) 0.9±1.0 0.6±1.3 0.42
FEV1 (ml) −76±244 52±192 0.11
FEV1pred. (%) −5.7±11.1 −0.1±9.1 0.15
FVC (ml) −62±242 35±203 0.14
Isometric muscle
force (nm)
−10±135 −46±135 0.41
1Values given as mean±SD.
2BMI; body mass index, FFM; fat free mass calculated from four standard
skinfold measurements, FEV1; forced expiratory volume in 1 s, FVC; forced
vital capacity, isometric muscleforce; summed maximal force in six muscle
groups.
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Anthropometric measurements were acquired prior to
exercise testing. Bodyweight was measured using a platform
beam balance (Mettler, Greifensee, Switzerland). Height was
measured with a stadiometer (Holtain, Crymich, UK). Body
mass index (BMI) was calculated as weight/height2. Body
composition, i.e. fat-free mass (FFM), was determined by
calculation from the sum of four standard skinfold-thickness
measurements [19–21].
2.3. Pulmonary function tests
Pulmonary function tests were performed after adminis-
tration of 800 μg of salbutamol, in order to rule out important
bronchial hyperreactivity. Forced vital capacity (FVC) and
forced expiratory volume in 1 second (FEV1) were obtained
from maximal expiratory flow–volume curves (Mastersc-
reen, Jaeger/Viasys, Hochberg, Germany). Values are
expressed as percent of predicted (pred) values as compared
to normal values for age and gender [22].
2.4. Peripheral muscle strength
Isometricmuscle forcewasmeasured for sixmuscle groups
on the non-dominant side of the patient, using a hand-held
dynamometer (Penny and Giles, Christchurch, UK). Maximal
voluntary force of the shoulder abductors, elbow flexors, wrist
extensors, hip and knee extensors, and ankle flexors were
measured as described by Backman et al [23]. Each muscle
group was tested three times, and the highest value obtained
was reported. Results for peripheral muscle force are presented
as the total maximal force (i.e., summed maximal force in six
muscle groups).
2.5. Exercise testing
Subsequent anaerobic and aerobic exercise tests were
performed on an electronically controlled resistance cycleergometer (Lode Examiner, Lode, Groningen, The Nether-
lands) as described by Klijn et al [24,25]. The Wingate
anaerobic test (WAnT) was used to assess short-term
anaerobic power. The WAnT comprises two parameters:
peak power (Ppeak; highest power during the test) and mean
power (Pmean; power averaged over 30 s). The subjects
rested for at least 45 min before aerobic fitness was assessed
by a standard progressive incremental exercise test (Wmax;
endurance). All subjects were familiar with the test
equipment. Verbal encouragement was given throughout
the tests to stimulate maximal performance.
2.6. Laboratory assays
2.6.1. Malondialdehyde
In the fasting state, prior to exercise testing, a venous
blood sample was drawn for malondialdehyde, vitamin E
(α-tocopherol) and A (retinol) measurement.
Malondialdehyde (MDA) levels were determined fluor-
imetrically (Fluostar Galaxy, BMG, Germany) by using the
TBARS (Thio Barbituric Acid Reactive Substances) method
according to Wasowics et al [26]. Serum concentrations of
α-tocopherol and retinol were determined simultaneously by
the standard reversed phase HPLC method used in our
hospital laboratory.
2.7. Data analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS, version 11.0 for Windows, Chicago,
IL). Since a cross-over design was used, and the results were
normally distributed, a simple paired Student t-test was used.
Data are presented as mean±SD.
3. Results
Baseline values of both groups were comparable. No
seasonal nor carry-over effect was seen in the groups starting
Table 5
Effect of micronutrient mixture (ML1) on anaerobic and aerobic
performance1,2
Changes
during ML1
Changes
during placebo
P value
Anaerobic performance
Ppeak (Watt) 52±100 104±160 0.16
Pmean (Watt) 32.6±49.6 50.3±109.3 0.29
Ppeak/FFM (Watt/kg LBM) 1.0±2.8 2.3±3.7 0.13
Pmean/FFM (Watt/kg LBM) 0.6±1.1 1.1±2.4 0.25
Aerobic performance
Wmax (Watt) −3.2±13.8 4.2±17.7 0.19
VO2 max (ml/kg/min) −1.5±3.5 0.3±3.9 0.10
1Values given as mean±SD.
2Ppeak; peak power measured by Wan T, Pmean; mean power measured by
WAnT, LBM; lean body mass, Wmax; cycling maximal workload, VO2max;
maximal oxygen consumption during bicycle ergometry.
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the 22 children with CF who completed the study are
presented in Table 2. All patients were adolescents with
an FEV1 pred of 87.2±17% (mean±SD). Baseline results
for anaerobic and aerobic performance are presented in
Table 3.
At the end of the three months intervention period the
plasma level of vitamin E had increased with 16.9±
11.6 μmol/l (from 11.7±7.4 μmol/l to 28.6±12.8 μmol/l),
while in the placebo group vitamin E levels had dropped
2.3±7.9 μmol/l (from 13.2±5.9 μmol/l to 11.0±6.1 μmol/l).
This difference in change between intervention and placebo
period is significant (P<0.001). The vitamin A levels too had
increased after the three months intervention period: from
1.01±0.3 μmol/l to 1.09±0.4 μmol/l, but were slightly lower
at the end of the placebo period (from 1.16±0.3 μmol/l to
1.09±0.4 μmol/l). This change of 0.09±0.17 μmol/l in the
intervention period versus −0.06±0.23 μmol/l in the placebo
period was not significant (P=0.06).Fig. 1. Correlation between change in vitamin E concentration and FEV1 and FVC
FVC, changes in forced vital capacity. Data are nonparametric and were analyzedHowever, for all other parameters no significant difference
was found. The change in nutritional parameters, BMI, FFM
and skinfolds, was essentially identical in the intervention
and the placebo period (Table 4). Also no significant
differences were seen in the change of any of the pulmonary
function tests under ML1 and placebo. Similar results were
seen for peripheral muscle strength, aerobic and anaerobic
muscle performance (Table 5). However, for the pulmonary
function tests FEV1, FVC, as well as for the aerobic Wmax,
and VO2max, and for the anaerobic Ppeak of WAnT a trend
towards significance was found for the placebo. Similarly we
found that plasma MDA concentrations decreased during
placebo (−0.263 μmol/l ±0.66 μmol/l), but marginally
increased during ML1 (0.023 μmol/l ± 0.61 μmol/l)
(P=0.15). During the intervention period six pulmonary
infections were reported (one needing IV antibiotics), as
opposed to eleven pulmonary infections in the placebo period
(four needing IV antibiotics). This difference was not
significant.
4. Discussion
In this study a mixture of multiple micronutrients, with
either muscle fortifying or antioxidant action, showed no
beneficial effects on either pulmonary function or muscle
performance in CF patients as compared to placebo.
Isometric muscle strength, anaerobic power (WAnT) and
endurance (Wmax, VO2max) were similar in the micronu-
trient and placebo group. A similar lack of effect has been
reported for triathlon athletes receiving antioxidant supple-
mentation [27]. Creatine, however, seems to improve
muscular performance, but most effectively in combination
with high-intensive training [28,29]. Also in these studies
much higher doses are used: initial loading dose of 20 g/d for
7 d, and a maintenance dose of 3–5 g/d versus 1.2 g/d in ourduring ML1. Delta FEV1, changes in forced expiratory volume in 1 s; delta
by using Spearman's rank correlation.
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patients showed a significant increase in maximal isometric
muscle strength, but no change in lung function after creatine
supplementation [30]. In this study also higher doses were
used (initial loading dosage 12 g/d first 7 d, maintenance
dose 6 g/d for 11 weeks). Taurine has been described as an
effective free radical scavenger and reportedly reduces
oxidative damage [31,32]. A positive correlation between
change in taurine concentration and changes in exercise time
to exhaustion and maximal workload (Wmax) was reported
in healthy young men after taurine supplementation [17].
Unfortunately, this intervention study lacked a control group,
so taurine might not be as effective as suggested.
Supplementation of L-carnitine has been reported to
normalize decreased levels induced by high-intensity
physical exercise [33,34]. So carnitine supplementation
may enhance performance in athletes, but healthy, essentially
sedentary persons and untrained individuals might not
benefit from supplementation.
We did not find any significant changes in pulmonary
function. A study by Wood et al. showed comparable results
after giving an antioxidant mixture for two months [12]. In
this study and ours, interestingly, a non-significant trend
towards the opposite was seen, as the decline in FEV1 and
FVC in the intervention group was higher. Moreover, in our
study plasma MDA concentration rose in the micronutrient
mixture group, and declined in the placebo group, suggesting
a shift to a pro-oxidative state when giving the micronutrient
combination. Negative effects of antioxidant supplementa-
tion, especially vitamin E, have been described by others,
and may play a role in our study [18,35–38]. AlthoughWood
et al. [12] did describe a correlation between an increase in
β-carotene plasma levels and an improvement in FVC, as
well as a correlation between an increase in plasma selenium
concentrations and an increase in FEV1, this does not imply
that exogenous administration of these substances does have
the desired beneficial effect on pulmonary function. In our
study too an increase in plasma vitamin E correlated with
increase in pulmonary function (P=0.04, Fig. 1).
Both the present report and the study by Wood et al. [12]
showed a trend towards a negative effect for pulmonary
function when administering a micronutrient mixture con-
sisting either partially or totally of antioxidants. Although it
has been thoroughly documented that low levels of
antioxidant molecules such as vitamin E and β-carotene
can be normalized in CF patients [8–10], so far no hard
evidence has been brought forward that boosting plasma
levels of these antioxidants reduces pulmonary deterioration.
A study by Renner et al. [11] showed that high dose β-
carotene supplementation does normalize plasma MDA
levels. However no effect on FEV1 was seen, although the
number of days on antibiotics was less in the intervention
group.
In conclusion, in the current study we found no
significant effects of a micronutrient mixture on either
muscle performance or pulmonary function. Therefore, webelieve that before conducting further studies with multiple
micronutrients, carefully designed interventions with single
antioxidants, including determination of the optimal
amount to normalize parameters of oxidative stress, are
warranted.
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